ARTBIO Secures $90 Million in Series A Financing

Clinical-stage radiopharmaceutical company ARTBIO has successfully secured $90 million in a Series A funding round to advance its portfolio of targeted alpha radioligand therapies (ARTs).

The funding round, jointly led by Third Rock Ventures and an undisclosed healthcare fund, includes participation from lead seed investors F-Prime Capital and Omega Funds. Earlier, in a seed funding round held in June 2023, ARTBIO raised a total of $23 million.

ARTBIO is dedicated to developing an innovative class of ARTs to enhance cancer care. The newly acquired funds will play a crucial role in fortifying the company’s Pb212 isolation technology, AlphaDirect, and supporting its distributed manufacturing strategy, ensuring consistent production and supply of ARTs.

The funding will be allocated to advance clinical trials for AB001 in the treatment of prostate cancer and to further the development of additional programs within the pipeline.

Share this:

Related Articles

Upcoming Events